Physician profile
Michele A Hauser
NPI 1912026592
$2,646.00
in general payments reported to CMS, 2019-2025
21 companies · $569 in 2025
The $569 reported for 2025 was more than what 78% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $59.08 · 2021: $40.03 · 2023: $137 · 2024: $785 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,487 · Education: $4.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,487.30 |
| Education | $4.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $676.49 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $441.29 | 2024-2025 | Caplyta |
| Abbvie INC. | $435.30 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $264.59 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $146.42 | 2019-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $129.83 | 2019-2025 | Trintellix |
| Allergan, INC. | $88.09 | 2019-2020 | |
| Alkermes, INC. | $75.64 | 2019-2025 | Lybalvi, Aristada |
| Bausch Health US, LLC | $56.90 | 2024 | Aplenzin |
| Inspire Medical Systems, INC. | $56.21 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $49.00 | 2025 | Spravato |
| Lilly USA, LLC | $33.54 | 2025 | Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $30.70 | 2025 | Auvelity |
| Shire North American Group INC | $30.03 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.41 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $19.73 | 2024 | Fanapt |
| Supernus Pharmaceuticals, INC. | $19.08 | 2025 | Qelbree |
| Corium, LLC | $18.34 | 2025 | Azstarys |
| Tris Pharma INC | $16.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.02 | 2025 | Cobenfy |
| Jazz Pharmaceuticals INC. | $15.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Hauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.